Cell Pryme-M is the one that exites me the most in short term, as if it can be incorporated via a simple manufacturing step change then we at likely to see deals relatively soon.
OmniCAR and Cell Pryme-A are 'patient touching' and therefore follow the standard Phase 1-3 requirements, albeit have read previously that the current CarT were approved after only Phase 2 due to the previously unheard of response and efficiency rates, but these platfotms are where the greatest gains will come from.
Cell Pryme-M is the one that exites me the most in short term,...
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
-0.001(2.27%) |
Mkt cap ! $35.43M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 4.3¢ | $15.15K | 352.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 203984 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 411268 | 4 |
View Market Depth
| Last trade - 10.06am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.3¢ |
Change
-0.001 ( 4.44 %) |
||||
| Open | High | Low | Volume | ||
| 4.3¢ | 4.3¢ | 4.3¢ | 25000 | ||
| Last updated 10.17am 17/05/2024 ? | |||||
| PTX (ASX) Chart |